Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma

Oncology

Volumn 72, Issue 5-6, 2008, Pages 347-356

  Lv, Huizhong ^a   Yu, Guangli ^a   Sun, Linlin ^b   Zhang, Zheng ^c   Zhao, Xia ^a   Chai, Wengang ^a,d  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b University Hospital   (China)

^c QINGDAO UNIVERSITY   (China)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Glycosaminoglycan; Hepatocellular carcinoma; Histological type; Intrahepatic cholangiocarcinoma; Primary hepatic carcinoma

Indexed keywords

CHONDROITIN SULFATE;

ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CARCINOMA; MOLECULAR SIZE; PRIORITY JOURNAL; PROGNOSIS;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CHOLANGIOCARCINOMA; CHONDROITIN SULFATES; GLYCOSAMINOGLYCANS; HUMANS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 39049169916     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113145     Document Type: Article

References (47)

1. Syrokou A, Tzanakakis GN, Hjerpe A, Karamanos NK: Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves growth factor receptors with tyrosine kinase activity. Biochimie 1999;81:733-744.
2. Syrokou A, Tzanakakis GN, Tsegenidis T, Hjerpe A, Karamanos NK: Effects of glycosaminoglycans in proliferation of epithelial and fibroblast human malignant mesothelioma cells. A structure-function relationship. Cell Prolif 1999;32:85-99.
3. Tzanakakis GN, Karamanos NK, Klominek J, Hjerpe A: Effects of glycosaminoglycans synthesis in cultured human mesothelioma cells of transforming, epidermal, and fibroblast growth factors and their combinations with platelet-derived growth factor. Exp Cell Res 1995;220:130-137.
4. Dobra K, Andäng M, Syrokou A, Karamanos NK, Hjerpe A: Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp Cell Res 2000;258:12-22.
5. Takeuchi J, Sobue M, Sato E, Shamoto M, Miura K, Nakagaki S: Variation in glycosaminoglycan components of breast tumors. Cancer Res 1976;36:2133-2139.
6. Iozzo RV, Wight TN: Isolation and characterization of proteoglycans synthesized by human colon and colon carcinoma. J Biol Chem 1982;257:11135- 11144.
7. Achilleas DT, Demitrios HV, Nikoletta P, Spyros SS, Dimitrios AT: Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003;35:376-390.
8. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA: Distribution and changes of glycosaminoglycans in neoplasias of rectum. Anticancer Res 1995;15:2107-2112.
9. Theocharis AD, Tsara ME, Pagageorgacopoulou N, Karavias DD, Theocharis DA: Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 2000;1502:201-206.
10. Iida S, Suzuki K, Matsuoka K, Takazono I, Shimada A, Inoue M, Yahara J, Noda S: Analysis of glycosaminoglycans in human prostate by high-performance liquid chromatography. Br J Urol 1997;79:763-769.
11. Yamori T, Ota DM, Cleary KR, Irimura T: Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin sulfate monoclonal antibody. J Cell Biochem 1988;36:405-416.
12. Denholm EM, Lin YQ, Silver PJ: Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation, and invasion. Eur J Pharmacol 2001;416:213-221.
13. Auvinen PK, Parkkinen JJ, Johansson RT, Agren UM, Tammi RH, Eskelinen MJ, Kosma VM: Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 1997;74:477-481.
14. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Agren U, Alhava E, Kosma VM: Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998;58:342-347.
15. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000;60:150-155.
16. Alini M, Losa GW: Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res 1991;51:1443-1447.
17. Ninomiya Y, Hata R, Nagai Y: Glycosaminoglycan synthesis by liver parenchymal cell clones in culture and its change with transformation. Biochim Biophys Acta 1980;629:349-358.
18. Cook GC: Hepatocellular carcinoma: one of the world's most common malignancies. Q J Med 1985;233:705-708.
19. Yu AS, Keeffe EB: Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8-24.
20. The Liver Study Group of Japan: Primary liver cancer in Japan: sixth report. Cancer 1987;60:1400-1411.
21. Gressner AM, Vasel A: Proteochondroitin sulfate is the main proteoglycan synthesized in fetal hepatocytes. Proc Soc Exp Biol Med 1985;180:334-339.
22. Dietrich CP, Sampaio LO, Toledo OMS, Cássaro CMF: Cell recognition and adhesiveness: a possible biological role for the sulfated mucopolysaccharides. Biochem Biophys Res Commun 1977;75:329-336.
23. Kojima J, Nakamura N, Kanatani M, Ohmori K: The glycosaminoglycans in human hepatic cancer. Cancer Res 1975;35:542-547.
24. Kovalszky I, Pogany G, Molar G: Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem Biophys Res Commun 1990;167:883-890.
25. Libbrecht L, Roskams T: Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol 2002;13:389-396.
26. Alison MR, Lovell MJ: Liver cancer: the role of stem cells. Cell Prolif 2005;38:407-421.
27. Sell S: Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect 1993;101(suppl 5):15-26.
28. Salmivirta M, Safaiyan F, Prydz K, Andresen MS, Aryan M, Kolset SO: Differentiation-associated modulation of heparin sulfate structure and function in CaCo-2 colon carcinoma cells. Glycobiology 1998;8:1029-1036.
29. Hamilton SR, Aaltonen LA: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System. Lyon, IARC Press, 2000, pp 165-166.
30. Zhang Z, Geng FS, Gao H: Isolation and purification of chondroitin sulfate from porcine cartilage. Chin J Biochem Pharm 2004;25:144-146.
31. Bitter T, Muir H: A modified uronic acid carbazole reaction. Anal Biochem 1962;4:330-334.
32. Hata R, Nagai Y: A rapid and micro method for separation of acidic glycosaminoglycan by two-dimensional electrophoresis. Anal Biochem 1972;45:462-468.
33. Newton DJ, Scott JE, Whiteman P: The estimation of acid glycosaminoglycan-Alcian blue complexes eluted from eletrophoretic strips. Anal Biochem 1974;62:268-273.
34. Ernst S, Langer R, Cooney CL, Sasisekharan R: Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol 1995;130:387-444.
35. Sampaio LO, Dietrich CP, Filho OG: Changes in sulfated mucopolysaccharide composition of mammalian tissues during growth and in cancer tissues. Biochim Biophys Acta 1977;498:123-131.
36. Gressner AM: Hepatic proteoglycans - a brief survey of their pathobiochemical implications. Hepatogastroenterology 1983;30:225-229.
37. Toyoki Y, Yoshihara S, Sasaki M, Konn M: Characterization of glycosaminoglycans in regenerating canine liver. J Hepatol 1997;26:1135-1140.
38. Engelmann S, Schwartz-Albiez R: Differential release of proteoglycans during human B lymphocyte maturation. Carbohydr Res 1997;32:85-95.
39. Iozzo RV, Cohen I: Altered proteoglycan gene expression and the tumor stroma. Experientia 1993;49:447-455.
40. Robinson HC, Dorfman A: The sulfation of chondroitin sulfate in embryonic chick cartilage epiphyses. J Biol Chem 1969;244:348-352.
41. Kolset SO, Kjiellén L, Seljelid R, Lindahl U: Changes in glycosaminoglycan biosynthesis during differentiation in vitro of human monocytes. Biochem J 1983;210:661-667.
42. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ: Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res 1999;59:2324-2328.
43. Béchard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P, Jude B, Janin A, Fernig DG, Tonnel AB, Lassalle P: Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001;276:48341-48349.
44. Kawashima H, Hirose M, Hirose J, Nagkubo D, Plaas AH, Miyasaka M: Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 2000;275:35448-35456.
45. Tang ZY: Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 2001;7:445-454.
46. Uhlman DL, Niehans DA: Immunohistochemical study of chondroitin-6- sulphate and tenascin in larynx: a loss of chondroitin-6-sulphate expression accompanies squamous cell carcinoma invasion. J Pathol 1999;189:470-474.
47. Kaczynski J, Hansson G, Wallerstedt S: Incidence, etiologic aspects and clinicopathologic features in intrahepatic cholangiocellular carcinoma: a study of 51 cases from a low-endemicity area. Acta Oncologica 1998;37:77-83.